Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study.

about

Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies

P2860

Q57074573-93086781-3C72-4245-BFBA-5A9BED5AD8C8

P2860

Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study.

Item

http://www.wikidata.org/entity/Q47663546

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Safety of galcanezumab in pati ...... d dose-ranging Phase 2b study.

@en

Safety of galcanezumab in pati ...... d dose-ranging Phase 2b study.

@nl

type

Item

label

Safety of galcanezumab in pati ...... d dose-ranging Phase 2b study.

@en

Safety of galcanezumab in pati ...... d dose-ranging Phase 2b study.

@nl

prefLabel

Safety of galcanezumab in pati ...... d dose-ranging Phase 2b study.

@en

Safety of galcanezumab in pati ...... d dose-ranging Phase 2b study.

@nl

P1476

Safety of galcanezumab in pati ...... d dose-ranging Phase 2b study.

@en

P2093

Angelo Camporeale

http://www.w3.org/2001/XMLSchema#string

Holland C Detke

http://www.w3.org/2001/XMLSchema#string

Joel R Saper

http://www.w3.org/2001/XMLSchema#string

Michael E Hodsdon

http://www.w3.org/2001/XMLSchema#string

Qi Zhang

http://www.w3.org/2001/XMLSchema#string

Tina Marie Myers Oakes

http://www.w3.org/2001/XMLSchema#string

Vladimir Skljarevsuki

http://www.w3.org/2001/XMLSchema#string

William Kielbasa

http://www.w3.org/2001/XMLSchema#string

P2860

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

Calcitonin gene-related peptide: physiology and pathophysiology

Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

The International Classification of Headache Disorders, 3rd edition (beta version)

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.

Therapeutic antibodies against CGRP or its receptor

The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF).

Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis.

The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs.

Current practice and future directions in the prevention and acute management of migraine.

P304

333102417747230

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0333102417747230

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29310444

http://www.w3.org/2001/XMLSchema#string

P921

migraine disorder

placebo

Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study.

about

P2860

P2860

Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P577

P698

P921